Interface Inc

Medium-term bullish momentum remains intact in this Stage 2 advance, supported by a clear higher highs and higher lows sequence and a rising 50-day MA. Short-term, price is encountering resistance at the flat to slightly declining 9/21 EMAs, making immediate entries unfavorable. The long-term uptrend is healthy above the rising 200-day MA. Execution is deferred until price shows structural absorption or a clean pullback into key support or the EMA zone.

• ↑Q1 2026 net sales $331M (+7% currency-neutral) and adjusted EPS $0.41 (+64% YoY).
• ↑'One Interface' strategy drove 29% healthcare sales growth and improved efficiency.
• ↓Geopolitical tensions could drive low single-digit input‐cost increases and squeeze margins.